TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: <h4>Background and objectives</h4>While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30-positive cutaneous T-cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.